Razelle Kurzrock, Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center, shared an article by Young Kwang Chae on X:
“Nivo/ipi is active in BAC. Some responses last for years.”
Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma).
Authors: Young Kwang Chae, et al.
